Answers are grounded in this paper and cite their sources.
BACKGROUND AND AIMS: This study evaluated the prognostic impact of epidermal growth factor receptor (EGFR) mutations in locally advanced non-small cell lung cancer (NSCLC) treated with definitive chemoradiotherapy (CRT) alone in cohorts in which consolidation durvalumab or osimertinib was not administered as part of the initial post-CRT strategy. METHODS: We systematically reviewed studies comparing CRT outcomes by EGFR status. Individual patient data were reconstructed from published Kaplan-Meier curves using the IPDfromKM method. The proportional hazards assumption was tested, and time-varying effects were modeled when this assumption was violated. The primary endpoints were progression-free survival (PFS) and overall survival (OS). RESULTS: Nine retrospective cohort studies involving 1,239 patients were included. Overall, PFS did not differ by EGFR status (hazard ratio [HR], 1.14; 95% confidence interval [CI], 0.98-1.33). In non-squamous NSCLC, PFS was significantly shorter in EGFR-mutant disease (HR, 1.37; 95% CI, 1.13-1.68). For OS, the proportional hazards assumption was violated. Median OS was 50.8 versus 34.9 months for EGFR-mutant and wild-type disease, respectively. The time-varying model showed a lower early hazard of death in EGFR-mutant disease, with attenuation of this advantage over time. The regression coefficients for EGFR mutation and the EGFR-by-log(time) interaction were -2.37 (standard error [SE], 0.55; p < 0.001) and 0.65 (SE, 0.17; p < 0.001), respectively. CONCLUSION: In CRT-only cohorts from the pre-PACIFIC/LAURA trial era, EGFR-mutant disease showed comparable overall PFS but shorter PFS in non-squamous NSCLC. Although median OS was longer in EGFR-mutant disease, the OS advantage narrowed over time.
No takes yet. Share an insight, caveat, or question.
Ochiai et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: